Serum Institute of India (SII) | The Business Standard
Skip to main content
  • Home
  • Economy
  • Stocks
  • Analysis
  • World+Biz
  • Sports
  • Splash
  • Features
  • Videos
  • Long Read
  • Games
  • Epaper
  • More
    • COVID-19
    • Bangladesh
    • Infograph
    • Interviews
    • Offbeat
    • Thoughts
    • Podcast
    • Quiz
    • Tech
    • Subscribe
    • Archive
    • Trial By Trivia
    • Magazine
    • Supplement
  • বাংলা
The Business Standard
SATURDAY, MAY 28, 2022
SATURDAY, MAY 28, 2022
  • Home
  • Economy
  • Stocks
  • Analysis
  • World+Biz
  • Sports
  • Splash
  • Features
  • Videos
  • Long Read
  • Games
  • Epaper
  • More
    • COVID-19
    • Bangladesh
    • Infograph
    • Interviews
    • Offbeat
    • Thoughts
    • Podcast
    • Quiz
    • Tech
    • Subscribe
    • Archive
    • Trial By Trivia
    • Magazine
    • Supplement
  • বাংলা

Serum Institute of India (SII)

Photo :UNB
Global Economy

Indian vaccine giant Serum plans African plant in global expansion

Adar PoonawallaPhotographer: Dhiraj Singh/Bloomberg
Coronavirus chronicle

Omicron-specific booster shot possible: SII CEO Adar Poonawalla

Serum Institute to resume supply of Covishield to Covax: Reports
Coronavirus chronicle

Serum Institute to resume supply of Covishield to Covax: Reports

A woman reacts as she receives a dose of the COVISHIELD vaccine, a coronavirus disease (COVID-19) vaccine manufactured by Serum Institute of India, in an alley at a slum area in Ahmedabad, India, September 28, 2021. REUTERS/Amit Dave
South Asia

India rules out reducing gap between Covishield doses

Students wearing protective face masks attend their class as they maintain social distancing after authorities reopened schools for classes for 10 and 12 after the schools were closed for months due to the coronavirus disease (COVID-19) outbreak, in Ahmedabad, India, January 11, 2021. REUTERS/Amit Dave/File Photo
Coronavirus chronicle

India allows Serum Institute to enrol 7-11 year olds in Novavax Covid-19 vaccine trial

A medical worker displays a vial with a coronavirus disease (Covid-19) vaccine at a vaccination centre in Tehran, Iran Sept 20, 2021. Majid Asgaripour/REUTERS
Coronavirus chronicle

India's Serum Institute to invest $68 million in UK vaccine maker Oxford Biomedica

Indian High Commissioner to Bangladesh Vikram Kumar Doraiswami. Photo: Collected
Covid-19 in Bangladesh

Bangladesh to get vaccines from India soon: Doraiswami

SII must return money if they fail to deliver vaccines: Health minister
Bangladesh

SII must return money if they fail to deliver vaccines: Health minister

Serum Institute of India to manufacture Sputnik V starting September
World+Biz

Serum Institute of India to manufacture Sputnik V starting September

A health official draws a dose of the AstraZeneca's Covid-19 vaccine manufactured by the Serum Institute of India, at Infectious Diseases Hospital in Colombo, Sri Lanka Jan 29, 2021. REUTERS/FILE
Coronavirus chronicle

India raises Covid vaccine production amid sharp dip in cases

FILE PHOTO: Vials of AstraZeneca's COVISHIELD, coronavirus disease (Covid-19) vaccine, are seen before they are packaged inside a lab at Serum Institute of India, Pune, India, Nov. 30, 2020. REUTERS/Francis Mascarenhas/File Photo
Coronavirus chronicle

SII seeks EU travel approval for its Covishield vaccine

Vials with a sticker reading, "COVID-19 / Coronavirus vaccine / Injection only" and a medical syringe are seen in front of a displayed Novavax logo in this illustration taken October 31, 2020. REUTERS/Dado Ruvic/Illustration/File Photo
Coronavirus chronicle

SII to introduce Novavax vaccine in India by September

FILE PHOTO: A Novavax logo is reflected in a drop on a syringe needle in this illustration taken November 9, 2020. REUTERS/Dado Ruvic/Illustration
Coronavirus chronicle

Novavax vaccine efficacy data promising; trials in advanced stage: Indian govt

  • Show More
The Business Standard
Top
  • Home
  • Entertainment
  • Sports
  • About Us
  • Bangladesh
  • International
  • Privacy Policy
  • Comment Policy
  • Contact Us
  • Economy
  • Sitemap
  • RSS

Contact Us

The Business Standard

Main Office -4/A, Eskaton Garden, Dhaka- 1000

Phone: +8801847 416158 - 59

Send Opinion articles to - oped.tbs@gmail.com

For advertisement- sales@tbsnews.net

Copyright © 2022 THE BUSINESS STANDARD All rights reserved. Technical Partner: RSI Lab